A universal surrogate peptide to enable LC-MS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein drug candidates in pre-clinical animal studies

Biomedical Chromatography

Volumn 26, Issue 8, 2012, Pages 1024-1032

  Furlong, Michael T ^a   Ouyang, Zheng ^a   Wu, Steven ^a   Tamura, James ^a   Olah, Timothy ^a   Tymiak, Adrienne ^a   Jemal, Mohammed ^a  

^a BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Bioanalysis; Fc region; LC MS MS; Therapeutic antibody; Universal surrogate peptide

Indexed keywords

ANIMALS; ASSAYS; MONOCLONAL ANTIBODIES;

BIOANALYSIS; FRACTION CRYSTALLIZABLE REGION; HUMAN ANTIBODIES; HUMAN MONOCLONAL ANTIBODIES; LC-MS-MS; LC.MS/MS; PLASMA SAMPLES; THERAPEUTIC ANTIBODIES; THERAPEUTIC PROTEIN; UNIVERSAL SURROGATE PEPTIDE;

PEPTIDES;

HUMAN MONOCLONAL ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2;

ARTICLE; DOG; DRUG DETERMINATION; GUINEA PIG; HUMAN; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PROTEIN DETERMINATION; RABBIT; RAT; RHESUS MONKEY; TANDEM MASS SPECTROMETRY;

ANIMALIA;

EID: 84864010690     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2759     Document Type: Article

References (29)

1. Beck A, Wagner-Rousset E, Bussat M-C, Lokteff M, Klinguer-Hamour C, Haeuw J-F, Goetsch L, Wurch T, Van Dorsselaer A and Corvaia N. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Current Pharmaceutical Biotechnology 2008; 9: 482-501.
2. Beck A, Wurch T, Bailly C and Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nature Reviews Immunology 2010; 10: 345-352.
3. Boyd RK, Basic C and Bethem RA (eds). Trace Quantitative Analysis by Mass Spectrometry. New York: John Wiley and Sons, 2008.
4. Chelius D, Rehder DS and Bondarenko PV. Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. Analytical Chemistry 2005; 77: 6004-6011.
5. Ezan E and Bitsch F. Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies. Bioanalysis 2009; 1: 1375-1388.
6. Fung EN, Xia Y-Q, Aubry A-F, Zeng J, Olah T and Jemal M. Full-scan high resolution accurate mass spectrometry (HRMS) in regulated bioanalysis: LC-HRMS for the quantitation of prednisone and prednisolone in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2011; 879: 2919-2927.
7. Gaza-Bulseco G, Li B, Bulseco A and Liu H. Method to differentiate Asn deamidation that occurred prior to and during sample preparation of a monoclonal antibody. Analytical Chemistry 2008; 80: 9491-9498.
8. Geiger T and Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. Journal of Biological Chemistry 1987; 262: 785-794.
9. Halquist MS and Thomas Karnes H. Quantitative liquid chromatography tandem mass spectrometry analysis of macromolecules using signature peptides in biological fluids. Biomedical Chromatography 2011; 25: 47-58.
10. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnology Progress 2005; 21: 11-16.
11. Jemal M and Xia YQ. Bioanalytical method validation design for the simultaneous quantitation of analytes that may undergo interconversion during analysis. Journal of Pharmaceutical and Biomedical Analysis 2000; 22: 813-827.
12. Kaufmann A, Butcher P, Maden K, Walker S and Widmer M. Quantitative and confirmative performance of liquid chromatography coupled to high-resolution mass spectrometry compared to tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2011a; 25: 979-992.
13. Kaufmann A, Butcher P, Maden K, Walker S and Widmer M. Semi-targeted residue screening in complex matrices with liquid chromatography coupled to high resolution mass spectrometry: current possibilities and limitations. Analyst 2011b; 136: 1898-1909.
14. 18O labels to monitor deamidation during protein and peptide sample processing. Journal of the American Society for Mass Spectrometry 2008; 19: 855-864.
15. Liu YD, van Enk JZ and Flynn GC. Human antibody Fc deamidation in vivo. Biologicals 2009; 37: 313-322.
16. Mesmin C, Fenaille F, Ezan E and Becher F. MS-based approaches for studying the pharmacokinetics of protein drugs. Bioanalysis 2011; 3: 477-480.
17. Nelson AL, Dhimolea E and Reichert JM. Development trends for human monoclonal antibody therapeutics. Nature Reviews. Drug Discovery 2010; 9: 767-774.
18. Ouyang Z, Furlong MT, Wu S, Sleczka B, Tamura J, Wang H, Suchard S, Suri A, Olah T, Tymiak A and Jemal M. Pellet digestion: a simple and efficient sample preparation technique for LC-MS/MS quantification of large therapeutic proteins in plasma. Bioanalysis 2012; 4: 17-28.
19. Patel K and Borchardt RT. Chemical pathways of peptide degradation. II. Kinetics of deamidation of an asparaginyl residue in a model hexapeptide. Pharmaceutical Research 1990; 7: 703-711.
20. Ramanathan R, Jemal M, Ramagiri S, Xia Y-Q, Humpreys WG, Olah T and Korfmacher WA. It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS. Journal of Mass Spectrometry 2011; 46: 595-601.
21. Ren D, Pipes GD, Liu D, Shih L-Y, Nichols AC, Treuheit MJ, Brems DN and Bondarenko PV. An improved trypsin digestion method minimizes digestion-induced modifications on proteins. Analytical Biochemistry 2009; 392: 12-21.
22. Strohl WR. Therapeutic monoclonal antibodies: past, present, and future. Therapeutic Monoclonal Antibodies 2009; 3-50.
23. Thomson R, Hodgman TC, Yang ZR and Doyle AK. Characterizing proteolytic cleavage site activity using bio-basis function neural networks. Bioinformatics 2003; 19: 1741-1747.
24. Wong RL, Xin B and Olah T. Optimization of Exactive Orbitrap acquisition parameters for quantitative bioanalysis. Bioanalysis 2011; 3: 863-871.
25. Wu ST, Ouyang Z, Olah TV and Jemal M. A strategy for liquid chromatography/tandem mass spectrometry based quantitation of pegylated protein drugs in plasma using plasma protein precipitation with water-miscible organic solvents and subsequent trypsin digestion to generate surrogate peptides for detection. Rapid Communications in Mass Spectrometry 2011; 25: 281-290.
26. Xia Y-Q, Lau J, Olah T and Jemal M. Targeted quantitative bioanalysis in plasma using liquid chromatography/high-resolution accurate mass spectrometry: an evaluation of global selectivity as a function of mass resolving power and extraction window, with comparison of centroid and profile modes. Rapid Communications in Mass Spectrometry 2011; 25: 2863-2878.
27. Yan B, Steen S, Hambly D, Valliere-Douglass J, Vanden Bos T, Smallwood S, Yates Z, Arroll T, Han Y, Gadgil H, et al. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. Journal of Pharmaceutical Sciences 2009; 98: 3509-3521.
28. Yang H and Zubarev RA. Mass spectrometric analysis of asparagine deamidation and aspartate isomerization in polypeptides. Electrophoresis 2010; 31: 1764-1772.
29. Zhang NR, Yu S, Tiller P, Yeh S, Mahan E and Emary WB. Quantitation of small molecules using high-resolution accurate mass spectrometers - a different approach for analysis of biological samples. Rapid Communications in Mass Spectrometry 2009; 23: 1085-1094.